CA2928736A1 — Inhaled aerosolized immuno-chemotherapy for the treatment of mdr tb
Assigned to Inspirx Inc · Expires 2015-05-07 · 11y expired
What this patent protects
The present disclosure relates to the treatment of tuberculosis and/or multi-drug resistant tuberculosis by inhalable pharmaceutical compositions that include an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimid…
USPTO Abstract
The present disclosure relates to the treatment of tuberculosis and/or multi-drug resistant tuberculosis by inhalable pharmaceutical compositions that include an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimidazole. The present disclosure also relates to an inhalable pharmaceutical composition that includes an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimidazole.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.